Czech National Bank Increases Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• The Czech National Bank has increased its stock position in Zimmer Biomet Holdings by 5.8%, owning a total of 48,361 shares valued at approximately $4.4 million as of the latest quarter.
• Zimmer Biomet recently announced a quarterly dividend of $0.24 per share, to be paid on October 31, representing a 1.0% dividend yield.
• Following various institutional investor activities, 88.89% of Zimmer Biomet's stock is now held by hedge funds and institutional investors.

Czech National Bank grew its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,361 shares of the medical equipment provider's stock after buying an additional 2,637 shares during the period. Czech National Bank's holdings in Zimmer Biomet were worth $4,411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in ZBH. Ameriprise Financial Inc. grew its stake in Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after acquiring an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock valued at $235,571,000 after purchasing an additional 1,488,918 shares in the last quarter. Nuveen LLC bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $155,891,000. Alyeska Investment Group L.P. bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $101,294,000. Finally, Boston Trust Walden Corp bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $54,108,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ZBH. Stifel Nicolaus lifted their price target on Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a report on Friday. Rothschild Redb upgraded Zimmer Biomet to a "strong-buy" rating in a report on Thursday. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. UBS Group raised their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Finally, Redburn Partners set a $130.00 target price on Zimmer Biomet in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $113.16.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded down $0.18 during trading hours on Friday, reaching $100.03. 4,228,497 shares of the stock traded hands, compared to its average volume of 1,180,396. The company's 50-day simple moving average is $100.06 and its two-hundred day simple moving average is $99.43. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The company has a market capitalization of $19.82 billion, a P/E ratio of 24.34, a price-to-earnings-growth ratio of 2.31 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company earned $2.01 EPS. Zimmer Biomet's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 23.36%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.39% of the stock is currently owned by insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.